ArticleMolecular cancer2015
Bergapten drives autophagy through the up-regulation of PTEN expression in breast cancer cells.
Article in Molecular cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Bergapten as a Multifunctional Phytochemical in Cancer Therapy: Mechanistic Insights, Pharmacokinetics, and Possible Nanotechnology-Enabled Formulation Strategies.Pharmaceutics · 2026Review
- Fingered Citron Volatile Oil: Extraction Methods, Chemical Composition, Biological Activity, and Product Development.Current issues in molecular biology · 2026Review
- Phytochemical basis and antitumor mechanisms ofFrontiers in immunology · 2026Review
- A Narrative Review on the Antitumoral Effects of Selected Mediterranean Plant Products from Southern Italy.International journal of molecular sciences · 2025Review
- Natural Small-Molecule Bergapten Ameliorates Amyloid-β Pathology and Neuroinflammation in Alzheimer's Disease.Nutrients · 2025Article
- Unveiling the therapeutic potential of HZQYF: exploring the inhibitory impact of a clinical herbal formula on gastric cancer through network pharmacology and transcript analysis.BMC complementary medicine and therapies · 2025Article
- Inhalable and bioactive lipid-nanomedicine based on bergapten for targeted acute lung injury therapy via orchestrating macrophage polarization.Bioactive materials · 2025Article
- LncRNA PTENP1/miR-21/PTEN Axis Modulates EMT and Drug Resistance in Cancer: Dynamic Boolean Modeling for Cell Fates in DNA Damage Response.International journal of molecular sciences · 2024Article
- Mechanisms of single herbs and herbal pairs in the treatment of mammary gland hyperplasia: An integrated review.Heliyon · 2023Review
- Evaluation of the Biological Effect of Non-UV-Activated Bergapten on Selected Human Tumor Cells and the Insight into the Molecular Mechanism of Its Action.International journal of molecular sciences · 2023Article
- Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling.Acta pharmacologica Sinica · 2022Article
- New and Emerging Targeted Therapies for Advanced Breast Cancer.International journal of molecular sciences · 2022Review
- Molecular docking analysis of phytochemicals with estrogen receptor alpha.Bioinformation · 2022Article
- PTEN alleviates maladaptive repair of renal tubular epithelial cells by restoring CHMP2A-mediated phagosome closure.Cell death & disease · 2021Article
- Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects.Molecules (Basel, Switzerland) · 2021Article
- A systems pharmacology approach to identify the autophagy-inducing effects of Traditional Persian medicinal plants.Scientific reports · 2021Article
- Polyphenol-Mediated Autophagy in Cancer: Evidence of In Vitro and In Vivo Studies.International journal of molecular sciences · 2020Review
- Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects.International journal of molecular sciences · 2020Review
- The Tumor SuppressorCells · 2020Review
- Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines.Journal of bone oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBergapten (5-methoxypsoralen), a natural psoralen derivative present in many fruits and vegetables, has shown antitumoral effects in a variety of cell types. In this study, it has been addressed how Bergapten in breast cancer cells induces autophagic process.
resultsIn MCF7 and ZR-75 breast cancer cells Bergapten exhibited anti-survival response by inducing the autophagic process increasing Beclin1, PI3KIII, UVRAG, AMBRA expression and conversion of LC3-I to LC3-II. LC3-GFP, Acridine orange assay and transmission electron microscopy even confirmed the increased autophagosome formations in treated cells. Bergapten-induced autophagy is dependent by PTEN up-regulation, since silencing this gene, the induction of Beclin1 and the p-AKT/p-mTOR signal down-regulation were reversed. PTEN is transcriptionally regulated by Bergapten through the involvement of p38MAPK/NF-Y, as evidenced by the use of p38MAPK inhibitor SB203580, site-direct mutagenesis of NF-Y element and NF-Y siRNA. Furthermore NF-Y knockdown prevented Bergapten-induced acid vesicular organelle accumulations (AVOs), strengthening the role of this element in mediating autophagy.
conclusionsOur data indicate PTEN as a key target of Bergapten action in breast cancer cells for the induction of autophagy. These findings add further details on the mechanism of action of Bergapten, therefore suggesting that phytochemical compounds may be implemented in the novel strategies for breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.